For the calendar quarter ending September 30, 2026, Bio-Techne Corp is expected to report consensus revenue of $292.6 million and adjusted EPS of $0.44, with its current stock price of $72.83 trading slightly above the average analyst price target of $70.50.
The central story for investors is the progress of the pending $11.3 billion acquisition by Merck KGaA, with markets seeking confirmation on the transaction's closing timeline following recent shareholder approval.
Analysts are also heavily scrutinizing organic revenue growth as an indicator of whether biopharma and academic research demand is stabilizing after a period of industry-wide budget tightening. Maintaining operational margins within the Diagnostics and Spatial Biology segments is viewed as a critical signal of the company's underlying health ahead of the merger's completion.